• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

作者信息

Kalemkerian Gregory P, Narula Navneet, Kennedy Erin B

机构信息

University of Michigan, Ann Arbor, MI; Weill Cornell Medicine, New York, NY; and American Society of Clinical Oncology, Alexandria, VA.

出版信息

J Oncol Pract. 2018 May;14(5):323-327. doi: 10.1200/JOP.18.00035. Epub 2018 Mar 28.

DOI:10.1200/JOP.18.00035
PMID:29589987
Abstract
摘要

相似文献

1
Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.用于选择接受靶向酪氨酸激酶抑制剂治疗的肺癌患者的分子检测指南：美国临床肿瘤学会对美国病理学家学会/国际肺癌研究协会/分子病理学协会临床实践指南更新的认可总结
J Oncol Pract. 2018 May;14(5):323-327. doi: 10.1200/JOP.18.00035. Epub 2018 Mar 28.
2
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.分子检测指南：选择肺癌患者接受靶向酪氨酸激酶抑制剂治疗：美国临床肿瘤学会对美国病理学家学院/国际肺癌研究协会/分子病理学会临床实践指南更新的认可。
J Clin Oncol. 2018 Mar 20;36(9):911-919. doi: 10.1200/JCO.2017.76.7293. Epub 2018 Feb 5.
3
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline.用于选择肺癌患者接受表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗的分子检测：美国临床肿瘤学会认可美国病理学家学会/国际肺癌研究协会/分子病理学协会指南
J Oncol Pract. 2015 Mar;11(2):135-6. doi: 10.1200/JOP.2014.002303. Epub 2014 Dec 16.
4
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22.
5
[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].[表皮生长因子受体酪氨酸激酶抑制剂在肺癌治疗中的敏感性与耐药性]
Magy Onkol. 2012 Mar;56(1):38-49. Epub 2012 Jan 15.
6
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.
7
What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies.肿瘤学家在酪氨酸激酶抑制剂治疗方面对病理学家的需求。
Arch Pathol Lab Med. 2019 Sep;143(9):1089-1092. doi: 10.5858/arpa.2019-0210-SA. Epub 2019 May 24.
8
Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.最佳一线间变性淋巴瘤激酶（ALK）靶向治疗。
Lung Cancer. 2017 Jul;109:147-148. doi: 10.1016/j.lungcan.2017.03.008. Epub 2017 Mar 20.
9
Tyrosine kinase inhibitors in lung cancer.肺癌中的酪氨酸激酶抑制剂。
Hematol Oncol Clin North Am. 2012 Jun;26(3):589-605, viii. doi: 10.1016/j.hoc.2012.02.001. Epub 2012 Mar 2.
10
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.使用小分子抑制剂靶向非受体酪氨酸激酶：近期进展综述
J Drug Target. 2016;24(3):192-211. doi: 10.3109/1061186X.2015.1068319. Epub 2015 Jul 27.

引用本文的文献

1
Prevalence of Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.越南早期非小细胞肺癌切除患者的突变患病率：EARLY-EGFR研究
Lung Cancer (Auckl). 2025 Apr 21;16:39-49. doi: 10.2147/LCTT.S494554. eCollection 2025.
2
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.实体瘤临床试验中的循环肿瘤DNA：挑战与当前应用
J Liq Biopsy. 2023 Aug 29;1:100007. doi: 10.1016/j.jlb.2023.100007. eCollection 2023 Sep.
3
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.
服务不足人群的分子预后/诊断研究的缺陷。
JCO Oncol Pract. 2024 Nov;20(11):1515-1522. doi: 10.1200/OP.24.00131. Epub 2024 Nov 12.
4
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.美国癌症协会国家肺癌圆桌会议战略计划：提高非小细胞肺癌综合生物标志物检测周转时间的方法。
Cancer. 2024 Dec 15;130(24):4200-4212. doi: 10.1002/cncr.34926. Epub 2024 Sep 30.
5
Unusual presentation of rearranged metastatic non-small cell lung cancer.重排转移性非小细胞肺癌的不寻常表现。
Respir Med Case Rep. 2024 Aug 18;51:102091. doi: 10.1016/j.rmcr.2024.102091. eCollection 2024.
6
Advancements of ALK inhibition of non-small cell lung cancer: a literature review.间变性淋巴瘤激酶（ALK）抑制剂治疗非小细胞肺癌的研究进展：文献综述
Transl Lung Cancer Res. 2023 Jul 31;12(7):1563-1574. doi: 10.21037/tlcr-22-619. Epub 2023 Jul 4.
7
The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.液体活检在非小细胞肺癌中的意义：潜力与期待。
Methods Mol Biol. 2023;2695:145-163. doi: 10.1007/978-1-0716-3346-5_10.
8
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.嵌合抗原受体T细胞对表达癌胚抗原相关细胞黏附分子5（CEACAM5）且对抗体-药物偶联物耐药的非小细胞肺癌细胞有效。
Front Oncol. 2023 Feb 27;13:1124039. doi: 10.3389/fonc.2023.1124039. eCollection 2023.
9
A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.基于铁死亡相关基因DNA甲基化数据的肺鳞状细胞癌新型预后标志物
J Oncol. 2022 Sep 12;2022:9103259. doi: 10.1155/2022/9103259. eCollection 2022.
10
Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges.基于循环肿瘤DNA的成人实体瘤基因组分析检测在精准肿瘤学中的应用：最新进展与未来挑战
Cancers (Basel). 2022 Jul 4;14(13):3275. doi: 10.3390/cancers14133275.